A Phase 2a, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety, Tolerability and Efficacy of Intravenous Bendavia (MTP-131) on Reperfusion Injury in Patients Treated With Standard Therapy Including Primary PCI and Stenting for ST-segment Elevation Myocardial Infarction.

Trial Profile

A Phase 2a, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety, Tolerability and Efficacy of Intravenous Bendavia (MTP-131) on Reperfusion Injury in Patients Treated With Standard Therapy Including Primary PCI and Stenting for ST-segment Elevation Myocardial Infarction.

Completed
Phase of Trial: Phase II

Latest Information Update: 16 Nov 2016

At a glance

  • Drugs Elamipretide (Primary)
  • Indications Myocardial reperfusion injury
  • Focus Therapeutic Use
  • Acronyms EMBRACE-STEMI
  • Sponsors Stealth BioTherapeutics
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 16 Nov 2016 Results of a subgroup analysis (n=271) presented at the 89th Annual Scientific Sessions of the American Heart Association
    • 15 Jun 2016 Results (n=100) of post-host analysis evaluating the association between infarct sixe and LV mass, published in the American Journal of Cardiology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top